Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics (Nasdaq: TNYA), a clinical-stage biotechnology company focused on heart disease therapies, has announced plans for a proposed public offering. The offering will consist of units comprising common stock and two series of warrants (Series A and Series B) to purchase common stock.
The company will also offer pre-funded units to certain investors, which include pre-funded warrants priced at $0.001 per share, along with Series A and Series B warrants. The pre-funded warrants will be immediately exercisable with no expiration date.
Leerink Partners and Piper Sandler are serving as joint bookrunning managers for the offering. The securities will be offered through a previously filed and SEC-approved Registration Statement on Form S-3. The completion, size, and terms of the offering remain subject to market conditions.
Tenaya Therapeutics (Nasdaq: TNYA), un'azienda biotecnologica in fase clinica focalizzata sulle terapie per le malattie cardiache, ha annunciato piani per una proposta di offerta pubblica. L'offerta consisterà in unità composte da azioni ordinarie e due serie di warrant (Serie A e Serie B) per l'acquisto di azioni ordinarie.
L'azienda offrirà anche unità pre-finanziate a determinati investitori, che includono warrant pre-finanziati a un prezzo di $0,001 per azione, insieme ai warrant delle Serie A e B. I warrant pre-finanziati saranno immediatamente esercitabili senza data di scadenza.
Leerink Partners e Piper Sandler fungono da gestori congiunti per l'offerta. I titoli saranno offerti attraverso una Dichiarazione di Registrazione già depositata e approvata dalla SEC sul modulo S-3. Il completamento, la dimensione e i termini dell'offerta rimangono soggetti alle condizioni di mercato.
Tenaya Therapeutics (Nasdaq: TNYA), una empresa de biotecnología en etapa clínica centrada en terapias para enfermedades cardíacas, ha anunciado planes para una oferta pública propuesta. La oferta consistirá en unidades que comprenden acciones ordinarias y dos series de warrants (Serie A y Serie B) para la compra de acciones ordinarias.
La empresa también ofrecerá unidades prefinanciadas a ciertos inversores, que incluyen warrants prefinanciados a un precio de $0.001 por acción, junto con los warrants de las Series A y B. Los warrants prefinanciados serán ejercitables de inmediato sin fecha de vencimiento.
Leerink Partners y Piper Sandler están actuando como gerentes conjuntos de la oferta. Los valores se ofrecerán a través de una Declaración de Registro previamente presentada y aprobada por la SEC en el formulario S-3. La finalización, el tamaño y los términos de la oferta siguen estando sujetos a las condiciones del mercado.
테나야 테라퓨틱스 (Nasdaq: TNYA), 심장병 치료에 중점을 둔 임상 단계의 생명공학 회사가 제안된 공모 계획을 발표했습니다. 이 공모는 보통주와 보통주를 구매할 수 있는 두 개의 시리즈의 워런트(시리즈 A 및 시리즈 B)로 구성된 유닛으로 이루어질 것입니다.
회사는 특정 투자자에게 사전 자금이 지원된 유닛도 제공할 예정이며, 이에는 주당 $0.001의 가격으로 사전 자금이 지원된 워런트와 함께 시리즈 A 및 B 워런트가 포함됩니다. 사전 자금이 지원된 워런트는 즉시 행사 가능하며 만료일이 없습니다.
리어링크 파트너스와 파이퍼 샌들러가 이 공모의 공동 주관사로 활동하고 있습니다. 증권은 이전에 제출되고 SEC의 승인을 받은 S-3 양식의 등록 신고서를 통해 제공될 것입니다. 공모의 완료, 규모 및 조건은 시장 상황에 따라 달라질 수 있습니다.
Tenaya Therapeutics (Nasdaq: TNYA), une société de biotechnologie en phase clinique axée sur les thérapies pour les maladies cardiaques, a annoncé des projets pour une offre publique proposée. L'offre consistera en des unités comprenant des actions ordinaires et deux séries de bons de souscription (Série A et Série B) pour l'achat d'actions ordinaires.
La société proposera également des unités préfinancées à certains investisseurs, qui incluent des bons de souscription préfinancés au prix de 0,001 $ par action, ainsi que des bons de souscription des Séries A et B. Les bons de souscription préfinancés seront immédiatement exerçables sans date d'expiration.
Leerink Partners et Piper Sandler agissent en tant que co-responsables de l'offre. Les titres seront offerts par le biais d'une déclaration d'enregistrement précédemment déposée et approuvée par la SEC sous le formulaire S-3. L'achèvement, la taille et les conditions de l'offre restent soumis aux conditions du marché.
Tenaya Therapeutics (Nasdaq: TNYA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Therapien für Herzkrankheiten konzentriert, hat Pläne für ein vorgeschlagenes öffentliches Angebot bekannt gegeben. Das Angebot wird aus Einheiten bestehen, die aus Stammaktien und zwei Serien von Warrants (Serie A und Serie B) zum Kauf von Stammaktien bestehen.
Das Unternehmen wird auch vorfinanzierte Einheiten für bestimmte Investoren anbieten, die vorfinanzierte Warrants zu einem Preis von 0,001 $ pro Aktie sowie die Warrants der Serien A und B umfassen. Die vorfinanzierten Warrants sind sofort ausübbar und haben kein Ablaufdatum.
Leerink Partners und Piper Sandler fungieren als gemeinsame Buchführer für das Angebot. Die Wertpapiere werden über eine zuvor eingereichte und von der SEC genehmigte Registrierungsanmeldung auf Formular S-3 angeboten. Der Abschluss, die Größe und die Bedingungen des Angebots unterliegen den Marktbedingungen.
- Multiple warrant series offering provides flexible funding options
- Pre-funded warrants feature immediate exercisability with no expiration
- Strong institutional backing with Leerink Partners and Piper Sandler as bookrunners
- Potential dilution for existing shareholders
- Offering size and terms undefined, indicating market uncertainty
- Additional share issuance may pressure stock price
Insights
Tenaya Therapeutics has announced plans to raise capital through a public offering of units combining common stock with Series A and B warrants. For certain investors, they're offering pre-funded units with immediately exercisable warrants. This financing move is significant for the clinical-stage biotechnology company with its
The offering structure reveals the company's strategic approach to capital raising. By including warrants alongside common stock, Tenaya is providing investors with potential upside through future equity participation while securing immediate funding. The pre-funded warrants option suggests flexibility designed to accommodate certain investors' preferences or regulatory considerations.
For a clinical-stage biotech focused on heart disease therapies, securing adequate funding is critical for advancing clinical programs. While the announcement doesn't specify the offering size or intended use of proceeds, biotechnology companies typically require substantial capital to fund clinical trials through to commercialization.
Existing shareholders should note the dilutive impact of this financing. The issuance of new shares and potential future dilution through warrant exercises will spread ownership across a larger share base. The market's reaction will likely depend on the pricing terms and discount to current trading levels, which remain undisclosed in this initial announcement.
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of
Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering.
The units and pre-funded units are being offered by Tenaya pursuant to a Registration Statement on Form S-3, which was previously filed and declared effective by the SEC, and Tenaya will file a preliminary prospectus supplement relating to and describing the terms of the proposed offering with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, statements relating to the offering, including the terms of the offering, the securities being offered and the timing of the closing of the offering. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not Tenaya will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering on the anticipated terms or at all, including the satisfaction of customary closing conditions; the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons; general economic and market conditions as well as geopolitical developments; and other risks. For further information regarding the foregoing and additional risks that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Tenaya in general, see Tenaya’s recent Quarterly Report on Form 10-Q filed on November 6, 2024, the prospectus supplement related to the proposed public offering we plan to file and subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ (formerly Stern Investor Relations)
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
FAQ
What type of securities is Tenaya Therapeutics (TNYA) offering in its latest public offering?
Who are the bookrunning managers for TNYA's proposed public offering?
What are the terms of the pre-funded warrants in TNYA's offering?
How is TNYA's new offering being registered with the SEC?
